Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.
FDA Approves Esketamine Nasal Spray for Treatment-Resistant Depression
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This approval applies to individuals who have had an inadequate response
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
Boing Boing on MSN1d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
BioSpace3d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...